The USC-UCLA Drug-Induced Liver Injury Clinical Center (CC) application in response to RFA-DK-13-003 """"""""Continuation and Expansion of the Drug Induced Liver Injury Network (DILIN)"""""""" hopes to continue to participate with the other CCs to advance the scientific knowledge and clinical evaluation of DILI. Our application will continue to combine the only two medical schools in Los Angeles County allowing us to continue to uniquely capture and enroll DILI cases into the Networks database supervised by the Data Coordinating Center (DCC). The 9.3 M residents of Los Angeles County (2011) are an unmatched resource composed of the most ethnically diverse population in the United States. Our application continues to utilize the expertise and talents from USC and UCLA medical centers. The enrollment of a large number of bona fide and ill patients with close follow up has demonstrated our CC's ability to capture DILIN cases in this diverse populations.
The Specific Aims for the continuation of the USC-UCLA DILI CC are to: 1) Continue enrollment of high quality cases with collection of disease controls and acute cases for mechanistic studies;2) Detailed analysis of cholestatic DILI due to HDS using genetic and serum analysis;3) Immunological surveying of acute DILI cases compared with disease control to identify potential mechanism of liver injury;4) Proteomic studies in acute cases of hepatocellular to identify mechanism of disease;and 5) Support of DILIN effort to develop assessment instruments and a treatment trial.

Public Health Relevance

Prescription and non-prescription medications, which include vitamins, herbal preparations, or, non-traditional forms of medicines, can very rarely cause significant liver injury. Because these events are so rare, the NIH has established a network of investigators to identify these rare causes of liver injury so that a shared database can be used for future studies. The USC-UCLA Drug-Induced Liver Injury Clinical Center wishes to continue to work with this established network to better understand causes of liver injury due to these agents.

Agency
National Institute of Health (NIH)
Institute
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Type
Research Project--Cooperative Agreements (U01)
Project #
5U01DK083020-07
Application #
8729479
Study Section
Special Emphasis Panel (ZDK1-GRB-N (M7))
Program Officer
Serrano, Jose
Project Start
2008-09-30
Project End
2018-06-30
Budget Start
2014-07-01
Budget End
2015-06-30
Support Year
7
Fiscal Year
2014
Total Cost
$334,892
Indirect Cost
$99,720
Name
University of Southern California
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
072933393
City
Los Angeles
State
CA
Country
United States
Zip Code
90089
Schmeltzer, Paul A; Kosinski, Andrzej S; Kleiner, David E et al. (2016) Liver injury from nonsteroidal anti-inflammatory drugs in the United States. Liver Int 36:603-9
Heidemann, Lauren A; Navarro, Victor J; Ahmad, Jawad et al. (2016) Severe Acute Hepatocellular Injury Attributed to OxyELITE Pro: A Case Series. Dig Dis Sci 61:2741-8
Bonkovsky, Herbert L; Kleiner, David E; Gu, Jiezhun et al. (2016) Clinical Presentations and Outcomes of Bile Duct Loss caused by Drugs and Herbal and Dietary Supplements. Hepatology :
Zheng, Elizabeth X; Rossi, Simona; Fontana, Robert J et al. (2016) Risk of Liver Injury Associated with Green Tea Extract in SLIMQUICK(®) Weight Loss Products: Results from the DILIN Prospective Study. Drug Saf 39:749-54
Hayashi, Paul H; Fontana, Robert J; Chalasani, Naga P et al. (2015) Under-reporting and Poor Adherence to Monitoring Guidelines for Severe Cases of Isoniazid Hepatotoxicity. Clin Gastroenterol Hepatol 13:1676-82.e1
Martinez, Melissa A; Vuppalanchi, Raj; Fontana, Robert J et al. (2015) Clinical and histologic features of azithromycin-induced liver injury. Clin Gastroenterol Hepatol 13:369-376.e3
Fontana, Robert J; Hayashi, Paul H; Barnhart, Huiman et al. (2015) Persistent liver biochemistry abnormalities are more common in older patients and those with cholestatic drug induced liver injury. Am J Gastroenterol 110:1450-9
Alqahtani, Saleh A; Kleiner, David E; Ghabril, Marwan et al. (2015) Identification and Characterization of Cefazolin-Induced Liver Injury. Clin Gastroenterol Hepatol 13:1328-1336.e2
Foureau, D M; Walling, T L; Maddukuri, V et al. (2015) Comparative analysis of portal hepatic infiltrating leucocytes in acute drug-induced liver injury, idiopathic autoimmune and viral hepatitis. Clin Exp Immunol 180:40-51
Usachov, Valentyn; Urban, Thomas J; Fontana, Robert J et al. (2015) Prevalence of genetic variants of keratins 8 and 18 in patients with drug-induced liver injury. BMC Med 13:196

Showing the most recent 10 out of 27 publications